丹参酮IIA预防和治疗PCI术后再狭窄的研究进展  

Research Progress of Tanshinone IIA in Preventing and Treating Restenosis after PCI

作　　者：庄欣莹 何雁雁 王尔凯 沙子又 马童童 

机构地区：[1]南京医科大学康达学院,江苏 连云港

出　　处：《临床医学进展》2023年第10期15736-15742,共7页Advances in Clinical Medicine

摘　　要：丹参酮IIA是多年生草本植物丹参的重要活性成分,其水溶性衍生物丹参酮IIA硫磺酸钠被广泛用于治疗心血管疾病。冠状动脉粥样硬化性心脏病患者的治疗常采用经皮冠状动脉介入手术(Percutaneous Coronary Intervention, PCI),PCI术后发生再狭窄是其较常见的并发症,且发生率逐年升高。目前PCI术后再狭窄主要是通过进行双联抗血小板治疗(DAPT,P2Y12受体拮抗剂与阿司匹林联合的方案)。但长期服用阿司匹林会出现抵抗现象、消化道出血、凝血时间延长和血小板减少等并发症,而配合使用丹参酮活性成分可达到类似的预防效果,而且可以降低凝血失衡相关的副作用。本文对近年来丹参酮IIA磺酸钠对于预防PCI术后再狭窄问题的研究进展进行探讨与总结。Tanshinone IIA is an important active component of Salvia miltiorrhiza, a perennial herb. Its wa-ter-soluble derivative, Tanshinone IIA sodium sulfoxylate, is widely used to treat cardiovascular diseases. Percutaneous coronary intervention (PCI) is often used to treat patients with coronary atherosclerotic heart disease. Restenosis after PCI is a common complication, and the incidence is increasing year by year. At present, restenosis after PCI is mainly treated by dual antiplatelet ther-apy (DAPT, P2Y12 receptor antagonist combined with aspirin). However, long-term use of aspirin will lead to complications such as resistance, gastrointestinal bleeding, prolonged coagulation time and thrombocytopenia. Combined use of tanshinone active ingredients can achieve similar preven-tive effects and reduce the side effects related to blood coagulation imbalance. In this paper, the ef-fects of sodium tanshinone IIA sulfonate on prevention of PCI in recent years are reviewed.

关 键 词：丹参酮IIA 冠状动脉介入术 支架内再狭窄 抗血栓 

分 类 号：R54[医药卫生—心血管疾病]